Beijing Disability Risk and Ageing Monitoring Study

Death Clinical Trial

— BEAM  

Official title:

Beijing Disability Risk and Ageing Monitoring Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06394817
• Other study ID #: 2022234
• Status: Recruiting
• Start date: February 20, 2023
• Est. completion date: May 2063

Study information

• Verified date: April 2024
• Source: Xuanwu Hospital, Beijing
• Contact: Yi Tang, MD., PhD
• Phone: 00861083199456
• Email: tangyi[@]xwhosp.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a community-based prospective cohort study in Beijing, China. The study has been initialized in 2023 and enrolled older residents. This study aims to develop disability risk assessment standards and an early warning model for older adults.

Description:

This is a community-based prospective cohort study. Individuals who aged 60 years or older, lived in the communities for more than 1 year, and signed the informed consent form were enrolled in the present study. The study has been initialized in 2023 and aimed to develop an early warning model and a series of disability risk assessment methods for older adults. This work consists of three steps as following. First, we will build a community-based cohort and thus set up a database. Second, an intelligence model for disability risk assessment will be developed using the database. Third, a series of procedures will be established according to the risk assessment model.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: May 2063
• Est. primary completion date: May 2063
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Aged 60 years or older
• Lived in the community for more than 1 year
• Signed the informed consent form

Exclusion Criteria:

• Cannot complete the survey

Related Conditions & MeSH terms

• Age Problem
• Death
• Disability

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
China	Xuanwu Hospital, Capital Medical University	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The prevalence and incidence of functional disability using a population-based survey	Functional disability was measured by Activities of Daily Living, cognitive function (Mini-Mental State Examination) and movement disorder(Short Physical Performance Battery) collected by questionnaires.The minimum value of the Activities of Daily Living is 0, and the maximum value is 100, the higher the score, the better the outcome.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.	An average of 1 to 2 years
Primary	The prevalence and incidence of mild cognitive impairment using a population-based survey	Mild cognitive impairment was measured using Mini-Mental State Examination collected by questionnaire.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.	An average of 1 to 2 years
Primary	The prevalence and incidence of dementia using a population-based survey	Dementia was determined by diagnosis of hospitalization or diagnosis of death or Clinical Dementia Rating scale. The minimum value of the Clinical Dementia Rating is 0, and the maximum value is 3, the higher the score, the worse the outcome.	An average of 1 to 2 years
Primary	The conversion rate of normal to mild cognitive impairment	Percentage of enrolled population that convert from normal to mild cognitive impairment	An average of 1 to 2 years
Primary	The conversion rate of mild cognitive impairment to dementia	Percentage of enrolled population that convert from mild cognitive impairment to dementia	An average of 1 to 2 years
Primary	The genetic and environmental factors for mild cognitive impairment and dementia at genomic and expression levels	Discover risk factors including genetic susceptibility loci (APOE genes and other risk genes) using gene sequencing, cardiovascular risk factors (blood glucose, cholesterol, homocysteine) using laboratory tests, and unhealthy lifestyle using questionnaire.	An average of 1 to 2 years
Primary	The biomarkers for normal, mild cognitive impairment, and dementia diagnosis	Humoral biomarkers are included Aß42, Aß40, phosphated tau and total tau in plasma, cerebrospinal fluid, saliva, and urine. Imaging biomarkers are included cerebral volume, glucose metabolism, amyloid and tau deposition of whole brain or hippocampus.	An average of 1 to 2 years
Primary	The prevalence and incidence of movement disorder using a population-based survey	Movement disorder was measured using Short Physical Performance Battery collected by questionnaire.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.	An average of 1 to 2 years